Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:37:50.313Z.
Calculation as of: 2026-10-06T16:37:50.313Z.
Quote observation: 2026-10-06T16:34:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a560454fa7ec99f8e1b664e45bbeeb036d535f564db40397f61edcd9a9056247
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$4.64M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.53M
Price/FCF Ratio
N/A
TTM Avg
63.09
3Y Avg
63.09
5Y Avg
63.09
Market Cap
$5.20M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $4.77M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.64M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.63M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.61M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.53M | N/A | 63.09 | 63.09 | 63.09 |
| Imunon, Inc. (IMNN)vs › | $5.02M | N/A | 15.88 | 17.94 | 17.94 |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.38M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.20M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.23M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
